Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

Phase 1Enrolling By InvitationNCT05143307

Excision BioTherapeutics9 enrolled

Overview

Participants who receive EBT-101 in a parent protocol will be eligible to participate in this long-term follow-up (LTFU) study (EBT-101-002).

Participants who receive EBT-101 in a parent protocol will be eligible to participate in this LTFU study (EBT-101-002). All participants will have follow-up visits every six months until Year 5 post EBT-101. Thereafter, all participants will have follow-up visits annually on the anniversary of EBT-101 administration until study completion at Year 15.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

HIV-1-infection

Interventions

EBT-101BIOLOGICAL

Long term follow up of participants who received EBT-101

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Willing and able to provide written, signed informed consent * Participants who received the investigational study intervention EBT-101 in a parent study Exclusion Criteria: • Participants who did not receive EBT-101 in a parent study

Locations (3)

Quest Clinical Research

San Francisco, California, United States

Washington University

St Louis, Missouri, United States

Cooper Health

Camden, New Jersey, United States

Outcomes

Primary Outcomes

Long-term safety of EBT-101

Long-term safety of EBT-101 will be assessed based on incidence and severity of clinically significant adverse events (AEs) according to Division of AIDS (DAIDS) 2017 over 15 years

Time frame: 15 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.